How Does Marburg Virus Enter Cells so Efficiently?

Key Takeaways

• Marburg entry protein 300× more efficient than Ebola’s
• Binds shared receptor in distinct orientation with higher affinity
• Structural shifts facilitate membrane fusion and cell entry
• Nanobody blocks protein, preventing viral entry in labs
• New assay enables fair comparison of viral entry proteins

Summary

University of Minnesota scientists pinpointed structural features of the Marburg virus entry protein that make it up to 300 times more efficient at infiltrating human cells than Ebola’s. By creating a tightly controlled assay, they showed the protein binds the shared human receptor in a unique orientation with higher affinity and undergoes shape changes that promote fusion. The team also identified a nanobody that can slip past the protein’s protective cap, bind the entry site, and block infection in laboratory models. These findings expose a clear therapeutic vulnerability in one of the deadliest filoviruses.

Pulse Analysis

Marburg virus, a member of the filovirus family, carries an average case‑fatality rate exceeding 70 percent, making it a persistent threat to global health security. While Ebola has dominated headlines, the mechanisms that grant Marburg its extraordinary lethality have remained obscure. By dissecting the virus’s entry protein, researchers have illuminated why Marburg can breach human cells far more effectively, a discovery that reshapes our understanding of viral pathogenesis and informs risk assessments for emerging outbreaks.

The Minnesota team engineered a pseudovirus platform that isolates the entry step, allowing a head‑to‑head comparison of Marburg and Ebola glycoproteins under identical conditions. Structural analyses revealed that Marburg’s glycoprotein engages the common NPC1 receptor from a different angle and with tighter binding, then undergoes a rapid conformational rearrangement that primes the viral membrane for fusion. These nuanced differences translate into a 300‑fold boost in entry efficiency, explaining the virus’s rapid replication and severe disease course.

Crucially, the study uncovered a nanobody that can bypass the glycoprotein’s protective cap, latch onto the receptor‑binding site, and halt cell entry in vitro. This proof‑of‑concept demonstrates a viable antiviral target and suggests that similar small‑molecule or antibody‑based therapies could be engineered against other high‑risk filoviruses. As the scientific community seeks broad‑spectrum countermeasures, the newly described assay and structural insights provide a roadmap for rapid drug screening and vaccine design, potentially curbing future Marburg outbreaks before they spread.